Cardiol's Heart Failure Treatment Offers Hope to Diabetics

By Kirsteen Mackay


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

We're discussing diabetes and heart failure with reference to Eli Lilly & Co. (NYSE: LLY), Novo Nordisk (NYSE: NVO), Sanofi (NASDAQ: SNY) and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL).

Doctor checking a patient by listening to his chest using a stethoscope

Diabetes and heart failure are closely linked. People with type 2 diabetes are two to four times more likely to develop heart failure than someone without diabetes. Heart failure is a condition in which the heart fails to efficiently pump oxygenated blood through the body, while diabetes is a condition that causes blood sugar levels to rise. Today we’ll be discussing this issue with reference to Eli Lilly & Co. (NYSE: LLY), Novo Nordisk (NYSE: NVO), Sanofi (NASDAQ: SNY) and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL).

The globally accepted treatment for diabetes is insulin, and big pharma companies Eli Lilly & Co., Novo Nordisk, and Sanofi all manufacture insulin to combat this debilitating disease. Meanwhile, heart failure comes in various forms, and some, such as acute myocarditis and diastolic heart failure, currently have no recognized standard of care.

With the conditions being so closely entwined, it makes sense that tackling one could reduce the risk of developing the other. While lifestyle changes can reduce the likelihood of heart failure, this is not as easy as it sounds. Every year, over 550k new cases are diagnosed in the U.S. That’s why Cardiol Therapeutics is working vigorously to develop therapeutic treatments to help people live more comfortably with this destructive disease.

Currently, the company has one multi-national clinical trial ongoing and another expected to commence shortly. Strong pre-clinical evidence shows the molecule being investigated could be a complete gamechanger, creating several reasons to invest in this exciting company.


Cardiol Therapeutics is a clinical-stage life sciences company focused on researching and developing an anti-fibrotic and anti-inflammatory therapy to treat cardiovascular disease (CVD). Its lead product candidate, CardiolRx™, is a pharmaceutically produced oral formulation being clinically developed for cardiovascular medicine use.

Based on an extensive review of the scientific literature on the subject, David Elsley, Cardiol’s President and CEO, along with his co-founders, discovered a molecule of strong interest in treating heart failure due to its anti-fibrotic, anti-inflammatory, and cardioprotective properties.


Diastolic heart failure represents around half of all heart failure. Furthermore, heart failure is possibly the most significant medical issue the western world faces. And this is rapidly escalating due to the rise of diabetes, obesity, and high blood pressure.

That’s why Cardiol Therapeutics has made treating diastolic heart failure its overarching goal, with its ongoing pre-clinical development of a solution its priority.

Cardiol’s administration of CardiolRx™ for acute myocarditis patients is in an oral formulation. For treating diastolic heart failure patients, the CardiolRx™ formulation is expected to be administered via subcutaneous injection, similar to the way people with diabetes use insulin.

The oral formulation of CardiolRx™ allows the treatment to be administered quickly and aggressively at very high doses. This is particularly important when dealing with acute myocarditis patients who require urgent care.

However, diastolic heart failure tends to be much more chronic than urgent and, in many cases, is something patients must learn to live with. That’s why a subcutaneous formulation is a more suitable form of treatment that could lead to less frequent dosing. Cardiol believes its subcutaneous formulation will allow it to be injected and taken up via the bloodstream.

Indeed, the company has some very compelling pre-clinical data that it presented at the American College of Cardiology’s (ACC) 69th virtual Annual Scientific Session & Expo together with the World Congress of Cardiology in 2020.

If Cardiol Therapeutics achieves its long-term goal of developing a treatment for diastolic heart failure, the addressable market is huge.

Indeed, this is a colossal health problem in the western world with no current standard of care. Plus, it is a condition that continues to grow in the developed world due to rising cases of diabetes, hypertension, and obesity.

The Cardiol Therapeutics team aspires to become a much bigger organization by developing life-changing drugs for this growing area of concern.

In achieving its ultimate objectives, Cardiol Therapeutics could give hope of better managing diastolic heart failure to all those suffering. Treating this serious health condition with a formulation that has an active pharmaceutical ingredient that’s structurally bioidentical to its organic counterpart and free from impurities could offer tremendous relief to many.

One of the reasons heart failure poses a mounting burden to the healthcare system is growing diabetes cases.

Eli Lilly & Co. (NYSE: LLY) uses biotechnology, chemistry, and genetic medicine, to advance new discoveries in redefining diabetes care and treating obesity. Its SURMOUNT-3 and 4 study varies from 72 to 88 weeks. SURMOUNT -1 will continue through 176 weeks to evaluate whether tirzepatide can slow the time to onset of type 2 diabetes in participants who had prediabetes at the time of entering the clinical trial.

Novo Nordisk (NYSE: NVO) aims to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. The company is paving the way for a Phase 3 program to discover the prospect of CagriSema in obesity and diabetes.

Sanofi’s (NASDAQ: SNY) recent type 1 diabetes study into second-generation insulins provides clinicians with valuable information. It shows how second-generation basal insulins compare to clinically relevant outcomes such as Time in Range, glucose variability, and hypoglycaemia.


In this article:




This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of One Hundred and Eighty Thousand Dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter